The investigation of the therapeutic efficacy of rapid intravenous immunoglobulin injection for acute phase Kawasaki disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014665

Enrollment

100

Registered

2014-07-27

Start date

2014-10-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki disease

Interventions

Freeze-Dried Sulfonated Human Normal Immunoglobulin 2g/kg (maximum administration rate 0.06ml/kg/min) Freeze-Dried Sulfonated Human Normal Immunoglobulin 2g/kg (maximum administration rate 0.03ml/kg/m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Kawasaki disease patients who are scheduled IVIG treatment

Exclusion criteria

Exclusion criteria: Patients with hypersensitivity to immunoglobulin. Patients with cardiac or liver dysfunction.

Design outcomes

Primary

Measure	Time frame
?Duration of fever from the initiation of IVIG	—

Secondary

Measure	Time frame
?WBC count and serum CRP, HDL-C and albumin levels before and after IVIG treatment ?Change of coronary artery diameter ?Clinical signs and symptoms, and laboratory blood markers before and after IVIG treatment ?Adverse event	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026